Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for long-acting peptide formulations has not progressed to a commercial licensing agreement, supporting the 87.5% market-implied odds against a deal by the October 7 resolution date. The October 2024 collaboration remains limited to a 14-month non-exclusive research pact focused on internal R&D assessment rather than technology transfer or binding commercial terms. Recent updates show continued joint research committee activity through mid-2026 alongside Lilly’s parallel partnerships, such as its Camurus obesity-drug delivery deal, without any disclosed advancement or negotiation milestones for SmartDepot. The short remaining window, typical multi-month timelines for pharma licensing due diligence, and Peptron’s focus on scaling its own manufacturing capacity further reduce the likelihood of a surprise announcement. Traders are watching for any official statements or filings in the coming weeks that could shift sentiment before the deadline.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% вероятность
$11,264 Объем
$11,264 Объем
7 окт. 2026 г.
13% вероятность
$11,264 Объем
$11,264 Объем
7 окт. 2026 г.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for long-acting peptide formulations has not progressed to a commercial licensing agreement, supporting the 87.5% market-implied odds against a deal by the October 7 resolution date. The October 2024 collaboration remains limited to a 14-month non-exclusive research pact focused on internal R&D assessment rather than technology transfer or binding commercial terms. Recent updates show continued joint research committee activity through mid-2026 alongside Lilly’s parallel partnerships, such as its Camurus obesity-drug delivery deal, without any disclosed advancement or negotiation milestones for SmartDepot. The short remaining window, typical multi-month timelines for pharma licensing due diligence, and Peptron’s focus on scaling its own manufacturing capacity further reduce the likelihood of a surprise announcement. Traders are watching for any official statements or filings in the coming weeks that could shift sentiment before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Открытие рынка: May 5, 2026, 8:02 PM ET
Объем
$11,264Дата окончания
7 окт. 2026 г.Открытие рынка
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for long-acting peptide formulations has not progressed to a commercial licensing agreement, supporting the 87.5% market-implied odds against a deal by the October 7 resolution date. The October 2024 collaboration remains limited to a 14-month non-exclusive research pact focused on internal R&D assessment rather than technology transfer or binding commercial terms. Recent updates show continued joint research committee activity through mid-2026 alongside Lilly’s parallel partnerships, such as its Camurus obesity-drug delivery deal, without any disclosed advancement or negotiation milestones for SmartDepot. The short remaining window, typical multi-month timelines for pharma licensing due diligence, and Peptron’s focus on scaling its own manufacturing capacity further reduce the likelihood of a surprise announcement. Traders are watching for any official statements or filings in the coming weeks that could shift sentiment before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Объем
$11,264Дата окончания
7 окт. 2026 г.Открытие рынка
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for long-acting peptide formulations has not progressed to a commercial licensing agreement, supporting the 87.5% market-implied odds against a deal by the October 7 resolution date. The October 2024 collaboration remains limited to a 14-month non-exclusive research pact focused on internal R&D assessment rather than technology transfer or binding commercial terms. Recent updates show continued joint research committee activity through mid-2026 alongside Lilly’s parallel partnerships, such as its Camurus obesity-drug delivery deal, without any disclosed advancement or negotiation milestones for SmartDepot. The short remaining window, typical multi-month timelines for pharma licensing due diligence, and Peptron’s focus on scaling its own manufacturing capacity further reduce the likelihood of a surprise announcement. Traders are watching for any official statements or filings in the coming weeks that could shift sentiment before the deadline.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы